Humacyte (HUMA) News Today

Humacyte, Inc. (NASDAQ: HUMA) has a near-term clinical and regulatory catalyst, but updated earnings forecasts are mixed, with several longer-dated estimates lowered.

• Positive Sentiment: Humacyte plans to present five ATEV and Symvess updates at the VEITHsymposium, including interim Phase 3 data in women receiving hemodialysis and integrated results from three dialysis-access trials. The company also expects to submit a supplemental BLA for hemodialysis access in November. The presentations may draw attention to its pipeline, though the data have not yet been presented. Humacyte VEITHsymposium announcement
• Positive Sentiment: StoneX reiterated its “Speculative Buy” rating, offering a supportive analyst view, although the reiteration itself is not a new upgrade. StoneX rating coverage
• Neutral Sentiment: HC Wainwright kept its “Buy” rating and raised its FY2026 and Q1 2027 EPS forecasts, but lowered several later-period estimates. The revisions are mixed overall.
• Negative Sentiment: The broker cut its Q3 and Q4 2027 forecasts by $0.01 per share each, lowered FY2027 estimates to a loss of $0.31 per share from $0.30, and reduced its FY2028 estimate to a loss of $0.11 from $0.07. These changes suggest weaker expected earnings further out.